Literature DB >> 8590993

Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat.

I Ostman-Smith1.   

Abstract

1. Studies on cardiac myocyte cell cultures have postulated a role for alpha 1-adrenoceptors and mechanical stretch in the induction of cellular changes thought to be important in compensatory cardiac hypertrophy. However, in vivo work suggests that beta-adrenoceptors are important and the present study was designed to analyse the effect of propranolol on the cardiac hypertrophy caused by a pressure-overload in a way that takes account of the effects of propranolol on the work load itself. 2. The compensatory cardiac hypertrophy that develops in response to experimental coarctation of the aorta was studied in the rat. Pressure gradients and total cardiac work load (expressed as rate x pressure product) were assessed, and the relationship between increasing cardiac work load and the resulting left ventricular hypertrophy was established in a control group and compared with left ventricular hypertrophy in a group treated with a high dose of oral propranolol (80 mg kg-1 body weight). 3. In the rats with mean pressure gradients over the coarctation in the range of 15-31 mmHg, the animals on control diet showed a 38% increase in left ventricular weight/body weight ratio (LV ratio) and a 30% increase in heart weight/body weight ratio (heart ratio), whereas rats given high dose oral propranolol-treatment showed increases of only 13% and 9%, respectively. 4. In a second series of rats with a wider range of pressure gradients, the regression lines of LV ratio versus mean pressure gradient, and of LV ratio versus cardiac work, were different in the two groups with a slope that was only half as steep in the propranolol-treated rats as in the controls. Thus, for the same increment in cardiac work load, the degree of compensatory cardiac hypertrophy in propranolol-treated rats was half that observed in controls. 5. The reduction in compensatory cardiac hypertrophy was not associated with an increase in incidence of congestive heart failure and the propranolol-treated rats were able to sustain equally high (or higher) degrees of pressure over-load as controls did. 6. It is concluded that propranolol treatment approximately halves the compensatory cardiac hypertrophy occurring in response to a left ventricular pressure over-load by a mechanism independent of its effect on cardiac work load. This finding provides further support for the view that noradrenaline released from sympathetic nerve terminals in the heart exerts a trophic effect on cardiac myocytes, and that the sympathetic nervous system may be the final common pathway in many forms of compensatory cardiac hypertrophy. In contrast to in vitro models, this effect appears to be largely mediated via beta-adrenoceptors in the intact animal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590993      PMCID: PMC1909123          DOI: 10.1111/j.1476-5381.1995.tb17230.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Proceedings of the british cardiac society.

Authors: 
Journal:  Br Heart J       Date:  1991-07

2.  Stretching cardiac myocytes stimulates protooncogene expression.

Authors:  I Komuro; T Kaida; Y Shibazaki; M Kurabayashi; Y Katoh; E Hoh; F Takaku; Y Yazaki
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

3.  Aortic pressure, substrate utilization and protein synthesis.

Authors:  H E Morgan; Y Kira; E E Gordon
Journal:  Eur Heart J       Date:  1984-12       Impact factor: 29.983

Review 4.  Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression.

Authors:  M van Bilsen; K R Chien
Journal:  Cardiovasc Res       Date:  1993-07       Impact factor: 10.787

Review 5.  Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy.

Authors:  I Ostman-Smith
Journal:  Clin Sci (Lond)       Date:  1981-09       Impact factor: 6.124

6.  Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.

Authors:  F M Fouad; Y Nakashima; R C Tarazi; E E Salcedo
Journal:  Am J Cardiol       Date:  1982-03       Impact factor: 2.778

7.  Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol.

Authors:  L Corea; M Bentivoglio; P Verdecchia; M Provvidenza; M Motolese
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-07

8.  Hemodynamic versus adrenergic control of cat right ventricular hypertrophy.

Authors:  G Cooper; R L Kent; C E Uboh; E W Thompson; T A Marino
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Adrenergic regulation of the skeletal alpha-actin gene promoter during myocardial cell hypertrophy.

Authors:  N H Bishopric; L Kedes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

10.  Hypoxic cardiac hypertrophy is not inhibited by cardioselective or non-selective beta-adrenoceptor antagonists.

Authors:  P Dennis; E M Vaughan Williams
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

View more
  4 in total

1.  Propranolol enhances cell cycle-related gene expression in pressure overloaded hearts.

Authors:  Marco Musumeci; Sonia Maccari; Paola Sestili; Michele Signore; Paola Molinari; Caterina Ambrosio; Tonino Stati; William H Colledge; Andrew A Grace; Liviana Catalano; Giuseppe Marano
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by beta-adrenergic signaling.

Authors:  Susanne Lutz; Roman A Mura; Hans Joerg Hippe; Christiane Tiefenbacher; Feraydoon Niroomand
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

3.  Propranolol causes a paradoxical enhancement of cardiomyocyte foetal gene response to hypertrophic stimuli.

Authors:  M Patrizio; M Musumeci; T Stati; P Fasanaro; S Palazzesi; L Catalano; G Marano
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 4.  Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?

Authors:  Alina Scridon; Alkora Ioana Balan
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.